Connect with us

Press Release

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Published

2 years ago

on

–News Direct–

By Jeremy Golden, Benzinga

Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023.

The randomized, controlled clinical trial is specifically looking into the safety and efficacy of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection if possible in borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Very encouraging results were recently reported by the Needham, Massachusetts-based company.

Patients reached an estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in the control group in PDAC. At 24 months, the survival rate was 71.4% in CAN-2409 treated patients compared to only 16.7% in the control group after chemoradiation. Thus, prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC. Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.0 months from enrollment. Only 1 out of 6 patients in the randomized control SoC chemotherapy group remained alive at the data cut-off (50.6 months).

No new safety signals were observed, providing further support that multiple injections of CAN-2409 are generally well tolerated. Additionally, there were no dose-limiting toxicities or cases of pancreatitis reported.

Previous analysis of resected tumors showed dense aggregates of immune cells including CD8+, cytotoxic tumor-infiltrating lymphocytes and dendritic cells in PDAC tissue after CAN-2409 administration. This reinforces the potential of CAN-2409 to activate a robust antitumoral immune response in patients with cancer also in cold, immunosuppressive tumors like PDAC.

Given the frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed, said Garrett Nichols, MD, MS, Chief Medical Officer of Candel. We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data in this randomized clinical trial. CAN-2409 was generally well tolerated without significant additional local or systemic toxicity when added to SoC chemoradiation.

Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf, replication-defective adenovirus designed to induce an individualized, systemic immune response against the tumor. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. More than 1,000 patients have been dosed with CAN-2409 to date, with a favorable reported tolerability profile and proof of concept in each indication that the company is currently pursuing.

CAN-2409 is injected directly into the tumor or target tissue using a localized injection method that is akin to the standard approach for in situ vaccination to elicit an immune response against the injected tumor and uninjected metastases.

Long-term survival data in PDAC was recently updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to Candel Therapeutics for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023. More recently, the FDA also granted Orphan Drug Designation.

The failure of conventional immunotherapy to improve outcomes in pancreatic cancer is attributed to the highly immunosuppressive tumor microenvironment, which is largely devoid of immune cells, said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. The immunological changes induced by CAN-2409, evident in the pancreatic tissue and the peripheral blood after administration, suggest that CAN-2409 is able to change the balance between the tumor and the patients anti-tumor immune response, which can convert progressive cancer into a chronic disease associated with improved survival.

Featured photo by National Cancer Institute on Unsplash.

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Aljanae Reynolds

+1 617-916-5445

areynolds@wheelhouselsa.com

Company Website

https://www.candeltx.com/

View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-reports-positive-data-from-phase-2-trial-of-can-2409-in-borderline-resectable-pancreatic-cancer-425692953

Candel Therapeutics

comtex tracking

COMTEX_453283087/2655/2024-06-03T08:31:08

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Loox launches Reviewers.com, the first product sampling platform built exclusively for Shopify brands

Published

8 hours ago

on

June 17, 2026

By

Tel Aviv, Israel, June 17th, 2026, FinanceWire

After a decade as the social proof leader trusted by 130,000 Shopify brands, Loox announces the public launch of Reviewers.com, a product sampling platform in the Shopify App Store that helps Shopify brands get high-quality video reviews at scale from a vetted community of everyday consumers. 

Why It Matters 

Consumer trust has never been lower due to the increase in synthetic content – AI-generated copy, fake reviews, and manufactured influencer content. Trust in brands is at an all-time low, and authentic social proof has never mattered more. Visual reviews build trust and convert browsers into buyers; they convert more than textual or photo reviews – but getting them in a consistent, scalable way has always been painfully hard. Not every customer has the setup, motivation, or time to record a high-quality video. Reviewers.com changes that. 

How It Works 

Reviewers.com connects Shopify brands with real, everyday consumers who are strictly screened for clear audio, good lighting, and on-camera presence before they can enter the community. It’s a predictable, scalable way to get high-quality, authentic video reviews on demand. Brands gift their products; reviewers post honest, authentic video reviews in return. Reviewers.com saves brands hundreds of hours spent on finding creators, coordinating shipping, and validating their content. Campaigns are created in just a few minutes, fully integrated into Shopify, and every review comes with full usage rights.

“The campaign was very easy to set up, the reviews came in quickly, and there were really good, thoughtful reviews,” said Nana Adwoa Denkyiraa, founder of Ayebea’s Sankofa Marketplace. 

Key use cases 

  • Creating a steady stream of fresh video content for marketing and ads 
  • Seeding social proof for new product launches 
  • Keeping review widgets on product pages fresh and compelling 
  • Capturing seasonal content throughout the year 
  • Showcasing reviews from consumers who mirror the brand’s target audience

From the CEO 

“After 10 years helping Shopify brands collect and display social proof, we kept seeing the same problem: brands know video reviews are the strongest way to build trust with visitors and turn browsers into buyers, but they have no reliable way to get them. Reviewers.com solves that – authentically, affordably, and at scale,” said Yoni Elbaz, CEO and Co-founder of Loox. 

How is it different 

Unlike Influencer and UGC Platforms, Reviewers.com is purpose-built for honest product reviews – not polished influencer content or scripted UGC. Reviewers.com helps brands collect more compelling content by delivering reviews that are: 

  • FTC compliant – transparently disclosed, no grey areas 
  • Authentic and unscripted – real people sharing honest opinions 
  • High-quality – reviewers are screened before joining, and each review submitted is screened for audio, lighting, and content. 
  • Fully licensed – brands receive complete usage rights to every video. 

Who are the Reviewers, and how are they vetted 

Reviewers are real, everyday consumers who love trying new products and sharing honest opinions. Every Reviewer in our community is carefully vetted. Before participating, each candidate submits a sample video that we personally review for authenticity, fluent English, clear sound, and good lighting. Only those who meet our high standards are approved as Reviewers. As they join campaigns, we apply the same criteria to every video they submit, ensuring quality is maintained and continually improved. 

Availability and Pricing 

Reviewers.com is available today in the Shopify App Store to any US-based Shopify brand. Pricing is based on a monthly subscription with no long-term commitment. The monthly subscription is $150, including one campaign, with additional campaigns available for $150 per campaign. Each campaign can include up to 10 items gifted. Each merchant receives a 30-day free trial, which includes one free campaign. 

Readers can visit Reviewers.com to learn more and to start your first campaign free.

Resources 

About Loox 

Loox is the leading social proof platform for Shopify brands, trusted by more than 130,000 brands worldwide. For over 10 years, Loox has helped merchants collect, display, and leverage customer reviews and photos to build trust and drive sales. 

About Reviewers.com 

Reviewers.com helps brands collect authentic, high-quality video reviews through a trusted community of vetted reviewers who are excited to try products for free in exchange for sharing their honest review. Launching a campaign takes just minutes. Simply create your campaign, gift your products, and we handle the rest – from matching you with the right reviewers who place their orders directly through your website. Within weeks, you’ll receive high-quality video reviews with full usage rights, ready to use across your marketing channels, social ads, email campaigns, landing pages, and product review widgets. Whether you’re launching a new product, targeting a new audience, preparing for a seasonal campaign, or refreshing your brand content, Reviewers.com gives you authentic video reviews tailored to every marketing need.

Contact

Chief Business Officer
Natasha Shine-Zirkel
Reviewers.com
merchant-support@reviewers.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Mita TechTalks Convenes 125 Investors and Builders in Punta Mita for an Invite-Only Summit on Bitcoin, AI, and Energy

Published

8 hours ago

on

June 17, 2026

By

Punta Mita, Mexico, June 16th, 2026, FinanceWire

Running October 25–27, the summit pairs beachfront sessions and private villa workshops built to turn three days of conversation into strategies attendees can act on.

Mita TechTalks, an invite-only summit on the convergence of Bitcoin, artificial intelligence, and energy, will gather 125 guests October 25–27, 2026, in Punta Mita, Mexico. The summit brings together high-net-worth investors, family office allocators, corporate leaders, and builders for three days of oceanside sessions, private workshops, and unhurried conversations along the most exclusive stretch of Mexico’s Pacific coast. 

Sessions take place at the Kupuri Beach Club, an oceanview, open-air venue inside the private, residential community of Punta Mita, home to the Four Seasons, St. Regis, Montage, and Pendry resorts and two Jack Nicklaus Signature golf courses. The agenda opens with a beachfront welcome dinner, followed by full sessions and private-villa breakout workshops, evening dinners under the palapa, and a closing afternoon of Jack Nicklaus Signature golf or ocean sports. Because guests and speakers stay within the same community for the full three days, the schedule gives way to long, off-record conversations, and the chance to build authentic relationships with the people rather than collect badges.

Confirmed speakers include Jeff Booth, founder of ego death capital and author of The Price of Tomorrow; Lisa Hough, founder of BTM Energy; Sam Callahan, Director of Strategy and Research at OranjeBTC; Andre Neves, ZBD Co-Founder & CTO and more. Additional speakers will be announced in the coming weeks.

The summit is built on a simple premise: Bitcoin, artificial intelligence, and energy are no longer separate stories. Bitcoin is moving onto corporate balance sheets and into treasury strategy, AI is working its way into finance and the Bitcoin economy, and the power demands of both AI data centers and Bitcoin mining are redrawing the energy map. Programming spans three tracks, covering macro and corporate strategy, energy, and AI, where speakers and guests dig into how the three feed one another.

“Technology is inherently deflationary, and AI is about to accelerate that beyond anything we’ve seen. The real question for investors and companies is how you position for a world where the cost of almost everything trends toward zero,” said Jeff Booth, founder of ego death capital and author of The Price of Tomorrow. “In a fast paced world, the most meaningful breakthroughs happen when you slow down. That’s what Mita TechTalks is built for, and it’s why Bitcoin, AI, and energy belong in the same room, in a place like Punta Mita.”

Mita TechTalks is organized by Lynne Bairstow and Israel Muñoz, partners at Base Layer Advisors and co-hosts of the Build With Bitcoin podcast. Bairstow began her career on Wall Street at Merrill Lynch before moving to Mexico, where she founded MITA Ventures in 2012 and has spent more than two decades backing early-stage tech across Mexico and Latin America; she is also a co-founder of La Casa de Satoshi, a Bitcoin and freedom-tech hub in Mexico City. Muñoz co-founded an early cross-border payments startup and helped launch 500 Startups’ Miami operation, and now invests in early-stage Bitcoin infrastructure ventures.

“Some of the best moments at these gatherings happen away from the sessions. They happen at dinner, walking the beach, in a villa after the sessions end,” said Bairstow. “When a small group of people share the same place for three days, you leave having actually gotten to know the people at the forefront of capital market innovation.”

“Bitcoin, AI, and energy are the technologies that will redefine the global economy,” said Muñoz. “We wanted to bring the people at the center of that shift together somewhere they could actually talk, and there’s no better place to do it than in Punta Mita.”

Registration is open by application at 2026.mitatechtalks.com. Passes are released in tiers starting at $2,750 and rising as each phase sells out, and the summit is capped at 125 guests; once that number is reached, registration closes. Every pass includes full access to sessions and workshops, all meals, and evening events. Punta Mita is located 40 minutes from Puerto Vallarta International Airport.

This year’s Mita TechTalks is supported by ArcadiaB as Platinum Partner and Punta Mita as Host Partner, with Base Layer Advisors and Build With Bitcoin as Organizing Partners and Forager and Gannett Trust as Bronze Sponsors. If you are interested in sponsoring, please contact lynne@baselayeradvisors.com. 

About Mita TechTalks 

Mita TechTalks is an invite-only summit exploring the intersection of capital markets, Bitcoin, artificial intelligence, and energy. Held in the private, gated community of Punta Mita on Mexico’s Pacific coast, it is designed for wealth managers, family offices, corporate executives, and industry leaders shaping the future of capital. Organized by Base Layer Advisors and Build With Bitcoin, the summit returns October 25–27, 2026. For more information, users can visit 2026.mitatechtalks.com.

Contact

Founder
Phil
21M Communications
phil@21mcommunications.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Nocera Strengthens AI Growth Strategy with Strategic Investment in CampaignPulse.ai

Published

8 hours ago

on

June 17, 2026

By

Englewood Cliffs, NJ, June 16th, 2026, FinanceWire

Nocera, Inc. (NASDAQ:NCRA) has taken another significant step in its transformation into a diversified technology holding company by announcing a strategic investment in CampaignPulse.ai, an emerging artificial intelligence company focused on simulation-driven campaign intelligence, predictive analytics, and decision-support technologies.

The investment underscores Nocera’s commitment to building a portfolio of innovative businesses positioned at the forefront of artificial intelligence and digital transformation. As organizations across industries increasingly seek data-driven tools to improve planning, communication, and operational effectiveness, CampaignPulse.ai is developing solutions designed to help users evaluate strategies before committing valuable resources in real-world environments.

Expanding Nocera’s AI Ecosystem

The investment aligns with Nocera’s broader vision of evolving into Nocera Holdings, a technology-focused platform targeting high-growth sectors including artificial intelligence, digital infrastructure, robotics, biotech, blockchain, and digital assets.

By adding CampaignPulse.ai to its growing portfolio, Nocera gains exposure to a rapidly emerging segment of the AI market focused on predictive analytics, audience intelligence, and advanced simulation technologies. These capabilities are increasingly viewed as essential tools for organizations seeking to make faster, smarter, and more informed decisions.

“Our investment in CampaignPulse.ai represents another important step in the execution of Nocera’s strategy to build a diversified portfolio of technology-driven businesses operating in high-growth markets,” said Andy Jin, Chief Executive Officer of Nocera.

Building the Future of Campaign Intelligence

CampaignPulse.ai is developing an innovative platform designed to leverage large language models and artificial intelligence to simulate audience reactions, test messaging effectiveness, and evaluate strategic outcomes before implementation.

The platform’s planned capabilities include:

  • AI-powered campaign simulations
  • Predictive audience intelligence
  • Message testing and optimization
  • Sentiment and narrative analysis
  • Strategic communications support
  • Reputation monitoring
  • Performance analytics and reporting
  • Content creation and campaign development tools
  • Localization and personalization technologies

By combining advanced AI with predictive modeling, CampaignPulse.ai aims to help organizations reduce uncertainty, improve communication effectiveness, and optimize resource allocation.

Addressing a Growing Market Opportunity

The global demand for AI-powered analytics and decision-support solutions continues to expand as businesses, governments, advocacy groups, and institutions seek more sophisticated ways to forecast outcomes and improve strategic planning.

Nocera believes that technologies capable of integrating simulation, predictive analytics, and audience intelligence will play an increasingly important role in helping organizations navigate complex decision-making environments.

CampaignPulse.ai’s development roadmap also includes the creation of a global ambassador network intended to accelerate market awareness, foster strategic partnerships, and support future platform adoption across international markets.

Long-Term Vision for Shareholder Value

The investment reflects Nocera’s ongoing strategy of identifying innovative companies that can benefit from the accelerating adoption of artificial intelligence. Through a combination of strategic investments, acquisitions, and partnerships, the company aims to build a scalable portfolio of technology businesses capable of delivering sustainable long-term growth.

“We are excited to welcome Nocera as a strategic investor and partner,” said Ash Wright, President of CampaignPulse.ai. “We believe the combination of AI-powered simulations, predictive analytics, and decision-support capabilities can create a powerful new approach to campaign intelligence and strategic communications.”

As Nocera continues its transformation into a diversified technology platform, investments such as CampaignPulse.ai demonstrate the company’s focus on emerging technologies that have the potential to reshape industries, improve efficiency, and create meaningful value for shareholders and stakeholders alike.

With artificial intelligence rapidly becoming a cornerstone of modern business strategy, Nocera’s latest investment positions the company to participate in one of the most dynamic and transformative sectors of the global economy.

For more information visit – https://www.nocera.company/

Contact

Public Relations
Jackson Phoenix
Phoenix MGMT & Consulting Group
PR@PhoenixMGMTConsulting.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us